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Abstract 
Background: Diabetic ketoacidosis (DKA) is a medical emergency with a high 
mortality rate and is associated with severe metabolic acidosis and dehydration. 
DKA patients have an increased risk of arterial and venous thromboembolism, 
however little is known about this metabolic derangement in the first 24 hours of 
admission and to assess its effect on coagulation. We therefore utilised a novel 
functional marker of clot microstructure (fractal dimension - df) to assess these 
changes within the first 24 hours. 
Methods: Prospective single centre observational study to demonstrate whether the 
tendency of blood clot formation differs in DKA patients.  
Results: 15 DKA patients and 15 healthy matched controls were recruited. Mean df 
in the healthy control group was 1.74 ± 0.03. An elevated df of 1.78 ± 0.07 was 
observed in patients with DKA on admission. The mean pH on admission was 7.14 ± 
0.13 and the lactate was 3.6 ± 2.0. df changed significantly in response to standard 
treatment and was significantly  reduced to 1.68 ± 0.09 (2-6 h) and to 1.66 ± 0.08 at 
24 h (p < 0.01 One-way ANOVA). df  also correlated significantly with lactate and pH 
(Pearson correlation coefficient 0.479 and -0.675 respectively, p < 0.05). 
Conclusions: DKA patients at presentation have a densely organising less 
permeable thrombogenic clot microstructure as evidenced by high df. These 
structural changes are due to a combination of dehydration and a profound 
metabolic acidosis, which was reversed with treatment. These changes were not 
mirrored in standard clinical markers of thrombogenicity. 





Diabetic ketoacidosis (DKA) is a life-threatening emergency caused by the absence 
of insulin leading to severe metabolic acidosis and dehydration. It is more common in 
Type 1 diabetes mellitus (DM), however it may occur in patients with Type 2 DM. 
Severe metabolic acidosis is caused by enhanced breakdown of fat leading to an 
increase in serum fatty acids subsequently metabolised to ketones (acetoacetic acid 
and β-hydoxybutyricacid) in the liver. Dehydration results from osmotic diuresis 
associated with hyperglycaemia [1]. Therefore, the treatment of DKA is insulin and 
fluid replacement [2]. DKA is associated with a very high mortality rate of 5.2% for a 
single admission and 23.4% for recurrent admissions [3]. 
It is estimated that the fluid loss in DKA is approximately 6-9 litres [4]. Dehydration 
can lead to an increase in whole blood viscosity [5] and thereby increased 
bioavailability of blood coagulation proteins and platelets. In addition, dehydration 
can impair microcirculation [6], blood rheology and blood composition [7]. These 
changes can lead to a hypercoagulable state increasing the risk of thrombosis [8, 9]. 
A previous study has demonstrated that patients with DKA have reduced Protein C 
activity (reduced fibrinolysis), low free Protein S and an increase in VWF (Von 
Willebrand factor) antigen activity [9]. In addition, it has been shown that extracellular 
acidosis down-regulates most platelet function and increases the neutrophil 
mediated inflammatory response [10]. However, the balance between 
thrombogenicity and hypercoagulability and the effect of DKA on the coagulation 
system and clot microstructure is poorly understood. 
 
One of the widely recognised complications of DKA is the potential for developing 
venous or arterial thrombosis. There are many published case reports, mainly in 
children that are associated with central line placement. However, apart from case 
reports, there is limited evidence which has shown what effect a severe metabolic 
acidosis and its treatment has on thrombogenicity and clot quality in the first 24 
hours. The overall risk for developing venous thromboembolism associated with 
diabetic hyperosmolarity during an episode is 1.7% [11]. In other non-ketotic 
conditions severe dehydration may lead to profound changes in coagulation [12]. In 
addition, it has also been shown in in-vitro studies in healthy individuals that the 
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artificial alteration of pH may have an effect on clot mass and development [13, 14]. 
However, in the acute setting the use of conventional coagulation biomarkers such 
as PT (prothrombin time) and aPTT (activated partial thromboplastin time) do not 
reflect the global coagulation picture nor coagulation defects and its final outcome on 
clot quality [15-17]. A novel functional biomarker namely fractal dimension (df) can be 
used to quantify the quality and arrangement of clot microstructure. df is measured 
using rheological methods in whole blood . Previous studies have demonstrated that 
df can detect both hypo and hypercoagulable changes in several acute vascular 
inflammatory conditions. In addition, previous studies has shown that in diseases 
where vascular changes and flow are altered this biomarker measures variation in 
the strength and elasticity of the clot’s microstructure. This feature is associated with 
the clot’s resistance to breakdown and associated with poorer outcome. 
Furthermore, df has also been validated against treatment were correction of the 
underlying disease process is associated with a return to a more loosely arranged 
clot microstructure [19-22]. In this study we measured throughout the acute phase in 
the first 24 hours the potential effects of thrombogenecity in DKA and also the effect 
of standard treatment on clot development and its characteristics. We compared 
these changes with standard kinetic and viscoelastic measurements used in the 





This prospective observational study on 15 patients was carried out in the 
Emergency Department and Intensive Care Department of a large teaching hospital. 
This study had full ethical approval from the South West Wales Research Ethics 
Committee (07/WMW02/34). From patients with capacity, an informed 2-stage 
written consent was obtained and for those who lacked capacity, an assent was 





Fifteen adult patients (>18 years) presenting with a clinical diagnosis of diabetic 
ketoacidosis (Figure 1) were recruited within the Emergency Department from 
October 2011 to March 2014. DKA was diagnosed in patients who met the following 
criteria; capillary blood glucose >11mmol/L, capillary ketones >3 mmol/L or urinary 
ketones >2 mmol/L  and venous pH <7.3 or venous bicarbonate <18mmol/L. A 
control group of 15 healthy volunteers from a similar demographic population group 
and matched for gender and age were recruited. All healthy volunteers were fully 
screened to ensure that they were not on any medication or disease process that 
either affect or alter coagulation profile or platelet function. Patients who were on 
anticoagulant therapy or had any disease that affects the coagulation profile e.g. 
renal failure, liver disease were excluded. All the patients received the standard 
treatment based on hospital guidelines for managing DKA.  
 
Blood sampling 
Blood samples were collected at three time points: 0 hour (at presentation to the 
Emergency Department), 2-6 hours and 24 hours atraumatically using a large bore 
needle. The initial 5mls of blood was discarded to avoid changes in the coagulation 
system that may be activated by injury to the blood vessel.  
 
Fractal Analysis of clot microstructure 
6.6mls of whole, unadulterated blood was transferred to the double concentric 
cylinder geometry on an AR-G2 controlled stress rheometer (TA Instruments, New 
Castle, DE, USA) at a temperature of 37oC (±0.1oC). The blood sample was then 
subjected to a shear stress at frequencies of 0.2Hz, 0.4309Hz, 0.9283Hz and 2Hz 
and the phase angle (δ) was measured with respect to time (s).The gel point 
analysis was obtained graphically from which the df  can be determined as has been 
described previously [19-22]. The relationship between df and clot mass at the gel 
point was assessed using a previously described computer model of random fractal 
aggregate growth and the relative normalised mass of the structure that is formed 
[23, 24]. This model of the relationship between df vs. clot mass is shown in Figure 1.   
 
Multiplate (platelet aggregometry) 
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3mls of blood was collected in a hirudin blood collecting tube containing recombinant 
hirudin: >15 ug/mL (Verum Diagnostica, Munich, Germany) as per manufacturer’s 
instructions to perform platelet analysis. 300µL of hirudinised blood was mixed with 
an equal volume of normal saline in the multiplate test cell and was then incubated at 
37oC for 3 minutes. Three agonists: 1) Adenosine diphosphate (ADP test, Verum 
Diagnostica GmbH), 2) Arachadonic acid test of cyclooxygenase activity (ASPI test, 
Verum Diagnostica GmbH), 3) Collagen (COL test, Verum Diagnostica GmbH) were 
then used to activate the samples. The area under the curve measurements 
(arbitrary units) were used for aggregometry measurements. The normal ranges 
were ADP test: 57 to 113U, ASPI test: 71 to 115U and COL test: 72 to 125 [25, 26]. 
Plateletcrit was not adjusted before aggregation measurements. 
 
Full blood count and coagulation 
4mls of the blood sample were collected into a plastic, full-draw dipotassium EDTA 
(K2 EDTA 7.2mg) vacutainer (Becton, Dickinson and Company, UK, Ref: 367839) 
and a full blood count performed (FBC) within 2 hours. Sysmex XE 2100 (Sysmex 
UK, Milton Keynes, UK) automated haematology analyser was used to analyse the 
FBC.  
 
3.5mls of blood samples were collected into a 3.2% (0.109 mol/l) sodium citrate 
vacutainer (Greiner Bio-One GmbH, Austria, Ref: 454327) to analyse standard 
markers of coagulation (PT, aPTT and fibrinogen using Sysmex CA1500) and 
markers of fibrinolysis (D-dimer using TriniLIA Auto-D-dimer® turbidimetric assay). 
Factor VIII activity was determined by an aPTT based one-stage assay, using 
appropriate factor deficient plasma and Actin FS aPTT reagent (Siemens Healthcare 
Diagnostics Products GmbH, Marburg, Germany).  
 
Rotational thromboelastometry (ROTEM) 
3.5mls of blood samples were collected into a sodium citrate tube to analyse 
inflammatory markers such as PCT (Procalcitonin), TNF-α (Tumour Necrosis 
Factor), IL-6 (Interleukin) and E-Selectin. ELISA (enzyme-linked immunosorbent 
assay) kits used platelet poor plasma as instructed by the manufacturer. 600µl of 





Statistical analysis was carried out with the Statistical Package for Social Sciences 
(SPSS) for Windows, version 22.0 (Armonk, NY: IBM Corp.). Values are reported as 
mean and standard deviation or median and interquartile range. To assess 
differences in the frequency distribution of nominal data parameters across groups, 
Pearson’s chi-squared test was used. Student’s T-test was used to assess mean 
differences in normally distributed data whereas Mann-Whitney was used to 
determine differences in non-normally distributed data. One-way ANOVA was used 
to determine differences between more than 2 groups. Data normality was assessed 
using Shapiro-Wilk test. 
 
Results 
Fifteen patients with diabetic ketoacidosis were included in the study and fifteen 
healthy volunteers were recruited as a matched control.  
 
Demographics 
The baseline characteristics of DKA patients are summarised in Table: 1.  
 
pH and df  
Mean df in the healthy control group was 1.74 ± 0.03. A significantly elevated df of 
1.78 ± 0.07 was observed in patients with DKA on admission (Figure 2). The mean 
pH on admission was 7.14 ± 0.13 and the lactate was 3.6 ± 2.0. df changed 
significantly in response to standard treatment (intravenous fluids and insulin 
infusion) and was reduced to 1.68 ± 0.09 (2-6hrs), followed by 1.66 ± 0.08 at 24 
hours (p <0.002 One-way ANOVA). df also correlated significantly with lactate and 
pH (Pearson correlation coefficient 0.479 and -0.675 respectively, p <0.05, Figure 2). 
 
Full Blood Count and Coagulation 
Haemoglobin, haematocrit and platelets were high during the initial presentation and 
this might be due to haemo-concentration due to dehydration. With fluid replacement 
the levels normalise, however it was not statistically significant for haemoglobin and 
haematocrit. The change in platelet count was statistically significant [Table 2]. PT, 
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APTT and Fibrinogen levels were not deranged at initial presentation of DKA 
patients and with standard treatment there were no significant changes even with 
haemodilution [Table: 2].  
 
Platelet aggregometry 
The multiplate (whole blood impedance aggregometry) analysis using ADP 
(adenosine diphosphate), ASPI (arachidonic acid) and COL (collagen) agonists 
showed an initial increased activity over all time points as described in previous 
studies. However, this has not reached statistically significant changes in platelet 




ROTEM was used to measure clot volume and mass as a standard clinical 
viscoelastic technique. There were no significant changes in CTINTEM (clotting 
time), CFINTEM (clot formation time) and MCFINTEM (maximum clot firmness). 
INTEM being intrinsic haemostasis system and EXTEM means extrinsic 
haemostasis system. Both the LI60INTEM (lysis index after 60 minutes) and 
LI60EXTEM were statistically significant (Table 4).  
 
D-dimer and inflammatory markers 
No statistical difference between D-dimer and other inflammatory markers was 




DKA is a common medical emergency associated with severe metabolic acidosis 
and dehydration and if untreated or not addressed urgently has high mortality. With 
standard treatment such as fluid replacement and administration of insulin, the pH 
and metabolic profile should significantly improve and normalise over 24 hours.  It is 
imperative therefore that clinicians have accurate, reproducible and validated 
biomarkers that urgently assess the changes in DKA’s pathophysiology, occurring 




One of the main complications of DKA in the first 24 hours is thromboembolic and 
this risk is maintained until discharge. In this study, we demonstrate that in patients 
who present with DKA, the conventional biomarkers of clotting do not change during 
the first 24 hours and there is no indication of a thrombotic state. All the patients 
followed standard protocol of fluid replacement and insulin with the aim of reducing 
blood sugar and correcting dehydration. The standard guideline for fluid replacement 
is 6L of crystalloid over 19 hours [26] and more if clinically indicated. All patients 
responded well to fluid replacement as indicated by a reduction in haematocrit, 
haemoglobin and fibrinogen from a high to normal limits. None of the patients had 
any underlying acute inflammatory or coagulopathy conditions as mirrored by normal 
inflammatory profile (CRP, IL6 and 8, E- selectin, Procalcitonin, Factor VIII) before 
and after treatment. Therefore, it is arguable that DKA in these patients does not 
show pro-inflammatory features but DKA induces some of the stress related 
physiological parameters of the SIRS criteria (Systemic Inflammatory Response 
Syndrome) most commonly tachycardia and tachypnoea.  
 
The primary clot microstructure of blood clots consists of entangled and branching 
fibrin fibres. The thinner fibres have more branch points compared to thicker fibres. 
There is a linear relationship between df and the amount of fibrin mass that is 
structurally organised within the normal blood clot [23, 24]. Our study demonstrates 
that the patients who were admitted with DKA had a tight fibrin clot structure (as 
indicated by high df 1.78 ± 0.07). The mean df in the healthy control group (n=15) 
was 1.74 ± 0.03 and was comparable to that published in previous studies of healthy 
volunteers [16]. In previous studies an increase in df was associated with highly 
dense fibrin clots which indicate a hypercoagulable state [26, 30, 31] and a decrease 
in df was associated with less dense fibrin clots indicating a hypocoagulable state 
[31, 32]. In contrast the standard kinetic markers, PT/ APTT as well as D-dimer did 
not have statistical change throughout the management, which would indicate the 
absence of clotting activation or evidence of a clot breakdown as seen by the D-
dimer result. Interestingly there was a slight but non-significant increase in platelet 
activity, but it did not reach statistical significance and returned rapidly to normal with 
treatment. There was significant reduction in the platelet count over 24 hours, which 
may be due to haemodilution from fluid replacement. We assessed clot mass using 
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standard thromoelastography. Although there was a slight reduction in clot mass and 
its development, CF/ CFT/ MCF that are indicators of clotting interestingly remained 
within normal limits. Only significant change we have seen was an increase in lysis 
time, however, it remained in normal range. Although ROTEM showed very little 
change in MCF and clot mass over 24 hours, the df showed a consistent and 
significant decrease in the mechanical strength of the clot. The ability of df to show 
accurate and specific changes in clot strength and mechanical properties as 
compared to other biomarkers were previously observed in septic shock patients 
[32].  
 
The effect of low pH in clot microstructure has previously been attempted mainly in 
laboratory studies in non-physiological conditions [14, 15].  In this study, it was 
difficult to assess the effect of pH alone because DKA is characterised by both low 
pH and severe dehydration.  As severe dehydration would have altered blood flow 
leading to increased thrombotic risk, we suspect that although pH may have an 
effect on clot microstructure as discussed in other studies, the two will have an 
added effect in abnormal clot development if untreated. It was demonstrated that 
both df and clot microstructure decreases with haemodilution in a previous study 
[33]. 
 
Follow up showed all patients were treated appropriately and conventionally. In this 
study, the combination of dehydration and low pH lead to a tight and mechanically 
strong clot, which changed with appropriate treatment, which was opposite to what 
was observed in conventional markers and ROTEM. The ability of df as a marker of 
clot microstructure is the summation of the global pathway of coagulation activation 
and therefore may be a more sensitive and global marker of haemostasis. This study 
gives further evidence of the importance of a new biomarker and further studies are 
required to validate its use further. In summary, in this study there is no indication of 
thrombogenicity in DKA patients if treated appropriately. However, this does not 
apply to the patient who gets admitted to the ward, because other factors such as 
comorbidities and immobilisation may increase VTE episodes.  
 
This study has a number of limitations. Firstly, this was a subgroup analysis of a 
larger study. Secondly, this was a single centre prospective observational study, 
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which was not powered for any clinical outcome, but was mechanistic in design. 
However, this study determines for the first time an association between changes in 
pH observed in DKA and mechanical clot properties. Further studies are required to 





We believe that this is the first study, which describes changes in clot microstructure 
associated with the changes in pH in metabolic acidosis. We show how acute 
physiological changes such as dehydration and pH, altered capillary blood flow and 
viscosity affecting clot microstructure and its changing characteristics to treatment. 
We also demonstrated that df was responsive to treatment and that it has the 
potential to act as a biomarker of clot microstructure and thrombogenicity during 
DKA and its therapeutic intervention. These microstructural changes are highly 
relevant to thrombotic changes in many diseases such as DKA.  Further studies are 
required to fully understand how the metabolic changes in DKA regulate df and 
hence thrombogenic events. 
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Table: 1. DKA patient baseline characteristics 
 













Age, mean ± SD 
 
45.6 ± 14.2 














44.7 ± 15.9 
pH 
 
7.1 ± 0.2 
HCO3 (mmol/L) 
 
8.9 ± 5.3 
Urea (µmol/L) 
 
13.7 ± 6.1 
Creatinine (µmol/L) 
 
180.7 ± 81.5 
16 
 
Table: 2. Shows the mean ± standard deviation SD for df, PT, APTT, 
Fibrinogen, Platelets, Haemoglobin and HCT at three time points 
 N Mean±SD  p-value 
df                               Baseline 
                                    2-6 hours 




1.78 ± 0.07 
1.68 ± 0.09 
1.66 ± 0.08 
0.002 
PT                               Baseline 
                                    2-6 hours 




10.94 ± 1.18 
10.97 ± 1.09 
11.26 ± 0.08 
0.813 
APTT                           Baseline 
                                    2-6 hours 




28.24 ± 6.29 
25.43 ± 2.78 
24.22 ± 2.70 
0.65 
Fibrinogen                 Baseline 
                                    2-6 hours 




3.15 ± 0.72 
3.18 ± 0.64 
3.21 ± 0.87 
0.980 
Platelets                     Baseline 
                                    2-6 hours 




328.53 ± 94.28 
274.40 ± 73.73 
227.23 ± 67.97 
0.008 
Haemoglobin             Baseline 
                                    2-6 hours 




13.51 ± 2.38 
12.53 ± 2.14 
11.74 ± 1.80 
0.103 
HCT                            Baseline 
                                    2-6 hours 




0.42 ± 0.08 
0.38 ± 0.06 













Table: 3. Multiplate analysis with three reagents (ADP- adenosine diphosphate, 
ASPI- arachidonic acid and COL- collagen agonist at three time points shows 
there is  no significant change in platelet aggregation 
 N Mean±SD p-value 
ADPAUC                     Baseline 
                                    2-6 hours 




95.46 ± 37.46 
90.09 ± 24.72 
69.31 ± 22.51 
0.70 
ASPIAUC                    Baseline 
                                    2-6 hours 




131.23 ± 48.91 
117.00 ± 42.71 
101.23 ± 36.40 
0.220 
COLAUC                     Baseline 
                                    2-6 hours 




104.62 ± 27.66 
95.36 ± 23.10 
81.31 ±25.52 
0.80 
Values reported as mean ± SD. Area under the curve for ADP test: 57 to 113U, ASPI 
test: 71 to 115U and COL test: 72 to 125. 
 
Table: 4. Rotational thromboelastometry at three time points shows that 
LI60INTEM and LI60EXTEM were statistically significant 
 N Mean±SD p-value 
CTINTEM                   Baseline 
                                    2-6 hours 




146.21 ± 26.02 
150.27 ± 31.45 
148.08 ± 39.26 
0.953 
CFTINTEM                 Baseline 
                                    2-6 hours 




64.93 ± 16.15 
64.27 ± 13.91 
64.92 ± 13.40 
0.992 
MCFINTEM               Baseline 
                                    2-6 hours 




60.64 ± 26.00 
68.00 ± 3.55 
60.42 ± 19.52 
0.577 
LI60INTEM                 Baseline 
                                    2-6 hours 




98.00 ± 1.54 
96.18 ± 2.93 
91.80 ± 2.94 
<0.0005 
LI60EXTEM                Baseline 
                                    2-6 hours 




96.42 ± 1.73 
94.73 ± 2.90 




Table: 5. No statistical difference in D-dimer or inflammatory markers at three 
time points. pH changed significantly with standard treatment over 24 hours 
   N 
 Mean±SD (* denotes 
median and IQR)   p-value 
D-Dimer Baseline*   11   338(97-784) 
  0.092 2 - 6 hours*   7  268(78-401) 
24 hours*   8   527(495-1042) 
CRP Baseline*   13   9(4-18)    
2 - 6 hours 
  1 
   
 
 
24 hours   0 .  
IL8 Baseline*   9   26(19-51) 
  0.273 2 - 6 hours*   7   19(12-21) 
24 hours*   7   25(16-32) 
E-Selectin Baseline   9   45 ± 27 
  0.793 2 - 6 hours   7   41 ± 17 
24 hours   7   50 ± 28 
PCT Baseline*   9   237(191-343) 
  0.700 2 - 6 hours*   6   473 ± 353 
24 hours*   7   337(178-432) 
IL6 Baseline*   9   32(8-35) 
  0.441 2 - 6 hours*   7   18(5-25) 
24 hours*   5   30(21-48) 
FVIII Baseline   11   359.3091 ± 184 
  0.113 2 - 6 hours   8   302.4875 ± 126 
24 hours   11   228.4455 ± 94 
pH Baseline   11   7.1409 ± 0.13 
  0.005 2 - 6 hours   6   7.2550 ± 0.05 










Figure: 1.The variation of the mass of a random fractal aggregate (RFA) as a 
function of fractal dimension. The magnitude of the RFA is normalised to the 
mean of the lowest mean value of df for the three time points of the DKA 
patients (which was df = 1.68 at 24hour sampling point). The dotted lines 
represent the mean df and corresponding normalised mass value for whole 
blood at: df=1.69, mass = 1.0; healthy control value (df=1.74, mass=2.0); and 
DKA on admission (df=1.78, mass=3.6). 
 
 
Figure: 2. Mean df in healthy and DKA group. Mean df in the healthy control 
group was 1.74 ± 0.03. An elevated df of 1.78 ± 0.07 was observed in patients 





Figure: 3. Shows the change in pH and df during 24 hour treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
